Targets and molecular mechanisms of triptolide in cancer therapy

被引：0

作者：

Cuicui Meng ^{[1
]}

Hongcheng Zhu ^{[2
]}

Hongmei Song ^{[1
]}

Zhongming Wang ^{[3
]}

Guanhong Huang ^{[3
]}

Defan Li ^{[3
]}

Zhaoming Ma ^{[3
]}

Jianhua Ma ^{[3
]}

Qin Qin ^{[2
]}

Xinchen Sun ^{[2
]}

Jianxin Ma ^{[3
]}

机构：

[1] Bengbu Medical College

[2] Department of Radiation Oncology,The First Affiliated Hospital of Nanjing Medical University

[3] Department of Radiation Oncology,Lianyungang No.2 People’s Hospital

来源：

Chinese Journal of Cancer Research | 2014年 / 26卷 / 05期

关键词：

Triptolide(TPL/TL); neoplasms; antineoplastic; cancer;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 ;

摘要：

Triptolide(TPL/TL) is a natural drug with novel anticancer effects. Preclinical studies indicated that TPL inhibits cell proliferation, induces cell apoptosis, inhibits tumor metastasis and enhances the effect of other therapeutic methods in various cancer cell lines. Multiple molecules and signaling pathways, such as caspases, heat-shock proteins, NF-κB, and deoxyribonucleic acid(DNA) repair-associated factors, are associated with the anti-cancer effect. TPL also improves chemoradiosensitivity in cancer therapy. Phase I trials indicate the potential clinical value of TPL use. However, further trials with larger sample sizes are needed to confirm these results.

引用

页码：622 / 626

页数：5

共 50 条

[21] Biochemical mechanisms and molecular interactions of vitamins in cancer therapy
Aborode, Abdullahi T.
Onifade, Isreal A.
Olorunshola, Mercy M.
Adenikinju, Gladys O.
Aruorivwooghene, Ibude J.
Femi, Adeboboye C.
Osayawe, Osasere Jude-Kelly
Osinuga, Abraham
Omojowolo, Ebenezer A.
Adeoye, Adekunle F.
Olapade, Segun
Adelakun, Ibrahim O.
Moyinoluwa, Ogundepo D.
Adeyemo, Oluwatosin M.
Scott, Godfred Y.
Ogbonna, Ruth A.
Fajemisin, Emmanuel A.
Ehtasham, Omama
Toluwalashe, Soyemi
Bakre, Adetolase A.
Adesola, Ridwan O.
Ogunleye, Seto C.
Anyanwu, Nnenna R.
Iorkula, Terungwa H.
CANCER PATHOGENESIS AND THERAPY, 2025, 3 (01): : 3 - 15
[22] Broad targeting of triptolide to resistance and sensitization for cancer therapy
Hou, Zhen-yan
Tong, Xiao-pei
Peng, Yong-bo
Zhang, Bi-Kui
Yan, Miao
BIOMEDICINE & PHARMACOTHERAPY, 2018, 104 : 771 - 780
[23] Adenosine-to-inosine RNA editing in cancer: molecular mechanisms and downstream targets
Cheng, Hao
Yu, Jun
Wong, Chi Chun
PROTEIN & CELL, 2024,
[24] Editorial: DNA methylation in cancer therapy: therapeutic targets and molecular mechanism
Yan, Guoyi
Duan, Shaofeng
Cai, Jinyang
FRONTIERS IN ONCOLOGY, 2024, 14
[25] Three targets in one complex: A molecular perspective of TFIIH in cancer therapy
Kuper, Jochen
Kisker, Caroline
DNA REPAIR, 2021, 105
[26] Molecular Targets of Nimbolide for Anti-Cancer Therapy: An Updated Review
Elumalai, Perumal
Ezhilarasan, Devaraj
Raghunandhakumar, Subramanian
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2022, 41 (02) : 69 - 88
[27] Bcl-2 family members as molecular targets in cancer therapy
Marzo, Isabel
Naval, Javier
BIOCHEMICAL PHARMACOLOGY, 2008, 76 (08) : 939 - 946
[28] RNA polymerase - An important molecular target of triptolide in cancer cells
Pan, Jingxuan
CANCER LETTERS, 2010, 292 (02) : 149 - 152
[29] Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances
Chen, Run-Ze
Yang, Fei
Zhang, Min
Sun, Zhi-Gang
Zhang, Nan
FRONTIERS IN ONCOLOGY, 2021, 11
[30] Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, Alessandra
Leboffe, Loris
De Marinis, Elisabetta
Pagano, Francesca
Cicconi, Laura
Rochette-Egly, Cecile
Lo-Coco, Francesco
Ascenzi, Paolo
Nervi, Clara
MOLECULAR ASPECTS OF MEDICINE, 2015, 41 : 1 - 115

← 1 2 3 4 5 →